
Akeso at ASCO 2026: China Biotech’s Coming of Age as Ivonescimab Beats Keytruda
Akeso’s Ivonescimab Data at ASCO 2026 Signals China’s Transition from Generic Drugs to Frontier Oncology Innovation China’s biotech sector has evolved from generic drug manufacturing to cutting-edge oncology research, with…







